Skip to main content

Eptifibatide Disease Interactions

There are 2 disease interactions with eptifibatide.

Major

Eptifibatide (applies to eptifibatide) renal dysfunction

Major Potential Hazard, High plausibility.

The use of eptifibatide is contraindicated in patients dependent of dialysis. Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min. Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients Clinical monitoring of renal function is recommended.

References

  1. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
Major

GpIIb/IIIa platelet inhibitors (applies to eptifibatide) bleeding risks

Major Potential Hazard, High plausibility. Applicable conditions: Brain/Intracranial Tumor, Thrombocytopathy, Cerebral Vascular Disorder, Hypertension, Coagulation Defect, Thrombocytopenia

The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.

References

  1. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L (1987) "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med, 82, p. 703-13
  2. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ (1994) "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol, 74, p. 1166-70
  3. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP (1996) "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol, 78, p. 1161
  4. (2001) "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc
  5. Adgey AA (1998) "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J, 135, s43-55
  6. Kleiman NS (1997) "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol, 80, b29-33
  7. The IMPACT-II Investigators (1997) "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet, 349, p. 1422-8
  8. The RESTORE Investigators (1997) "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation, 96, p. 1445-53
  9. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
View all 9 references

Eptifibatide drug interactions

There are 146 drug interactions with eptifibatide.

Eptifibatide alcohol/food interactions

There is 1 alcohol/food interaction with eptifibatide.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer